TY - JOUR
T1 - Correction to
T2 - Saratale et al. Significance of Immune Status of SARS-CoV-2 Infected Patients in Determining the Efficacy of Therapeutic Interventions. J. Pers. Med. 2022, 12, 349
AU - Saratale, Ganesh Dattatraya
AU - Shin, Han Seung
AU - Shinde, Surendra Krushna
AU - Kim, Dae Young
AU - Saratale, Rijuta Ganesh
AU - Kadam, Avinash Ashok
AU - Kumar, Manu
AU - Bahkali, Ali Hassan
AU - Syed, Asad
AU - Ghodake, Gajanan Sampatrao
N1 - Publisher Copyright:
© The Authors.
PY - 2022/6
Y1 - 2022/6
N2 - Errors in Figures and Table Caption In the original publication [1], there were mistakes in the legends for Figure 1, Figure 2, and Table 1. We failed to mention the citation number in these legends. The correct legends appear below. Figure 1. Emerging therapeutic approaches against COVID-19 disease: (1) antibodybased therapeutics against the S protein (either via adoptive transfer of vaccination) to avoid progression of severe infections; (2) application of protease inhibitors against serine protease (TMPRSS2) prevents cleavage of S protein; (3) SRS-CoV-2 virus-specific memory CD8+ T cells from vaccination or earlier infection; (4) a new treatment approach targets the symptoms of cytokine storm, wherein the blood of infected patients is passed through customized filtration columns to capture pro-inflammatory cytokines before the pureblood returns to patients. Adapted and modified from [63]. Figure 2. Cytokine pathogenesis of SARS-CoV-2 infection. Intensive care or appropriate treatment is recommended for hospitalized severe SARS-CoV-2 patients who exhibit elevated levels of biomarkers in blood plasma: alveolar cell (AC), angiotensin-converting enzyme 2 (ACE2), atopic dermatitis (AD), ancestry clusters (AC1-4) granulocyte-macrophage colony–stimulating factor (GM–CSF), granulocyte colony–stimulating factor (G–CSF or GCSF), interleukin (IL), interferon (INF), monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory proteins (MIP1), natural killer (NK), polymorphonuclear granulocyte (PMN), T-effector cell (TEFF cell), tumor necrosis factor (TNF), regulatory T cell (Treg cell). Adapted and modified from [116]. Table 1. Mechanism of types of drugs and therapies useful in the treatment of SARSCoV- 2-infected patients [3,27,32]. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. These corrections were approved by the Academic Editor. The original publication has also been updated.
AB - Errors in Figures and Table Caption In the original publication [1], there were mistakes in the legends for Figure 1, Figure 2, and Table 1. We failed to mention the citation number in these legends. The correct legends appear below. Figure 1. Emerging therapeutic approaches against COVID-19 disease: (1) antibodybased therapeutics against the S protein (either via adoptive transfer of vaccination) to avoid progression of severe infections; (2) application of protease inhibitors against serine protease (TMPRSS2) prevents cleavage of S protein; (3) SRS-CoV-2 virus-specific memory CD8+ T cells from vaccination or earlier infection; (4) a new treatment approach targets the symptoms of cytokine storm, wherein the blood of infected patients is passed through customized filtration columns to capture pro-inflammatory cytokines before the pureblood returns to patients. Adapted and modified from [63]. Figure 2. Cytokine pathogenesis of SARS-CoV-2 infection. Intensive care or appropriate treatment is recommended for hospitalized severe SARS-CoV-2 patients who exhibit elevated levels of biomarkers in blood plasma: alveolar cell (AC), angiotensin-converting enzyme 2 (ACE2), atopic dermatitis (AD), ancestry clusters (AC1-4) granulocyte-macrophage colony–stimulating factor (GM–CSF), granulocyte colony–stimulating factor (G–CSF or GCSF), interleukin (IL), interferon (INF), monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory proteins (MIP1), natural killer (NK), polymorphonuclear granulocyte (PMN), T-effector cell (TEFF cell), tumor necrosis factor (TNF), regulatory T cell (Treg cell). Adapted and modified from [116]. Table 1. Mechanism of types of drugs and therapies useful in the treatment of SARSCoV- 2-infected patients [3,27,32]. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. These corrections were approved by the Academic Editor. The original publication has also been updated.
UR - http://www.scopus.com/inward/record.url?scp=85132378472&partnerID=8YFLogxK
U2 - 10.3390/jpm12060967
DO - 10.3390/jpm12060967
M3 - Comment/debate
AN - SCOPUS:85132378472
SN - 2075-4426
VL - 12
JO - Journal of Personalized Medicine
JF - Journal of Personalized Medicine
IS - 6
M1 - 967
ER -